Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296314 | 0.91 | GPR119 (0.49) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL2387633 | 0.91 | GPR119 (0.44) | GPR119KCNH2ACACB | |
| SCHEMBL1296758 | 0.89 | GPR119 (0.53) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL1295964 | 0.88 | GPR119 (0.53) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL1296176 | 0.88 | GPR119 (0.49) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL1296556 | 0.87 | GPR119 (0.52) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL1295786 | 0.86 | GPR119 (0.52) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL1295481 | 0.86 | GPR119 (0.52) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL1295450 | 0.86 | GPR119 (0.47) | GPR119CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL1295452 | 0.86 | GPR119 (0.47) | GPR119CHRM2CHRM1CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212939-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885CHRM2 586/4885CHRM1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.